Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3748 - Differences in gastric adenocarcinoma patients at extremes of the age spectrum


08 Oct 2016


Poster Display


Ryan Rhome


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


R. Rhome1, U. Ozbek2, R.F. Holcombe3, M. Buckstein4, C. Ang5

Author affiliations

  • 1 Radiation Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, 10029 - New York/US
  • 2 Biostatistics, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 3 Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 4 Radiation Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 5 Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 10029 - New York/US


Abstract 3748


Patients (pts) at the extremes of the age spectrum are often under-represented in gastric cancer trials (median age of inclusion was 56-62 years old (y/o) in major studies). Large population-based databases are useful to characterize the demographics, treatment patterns, and outcomes of these pts.


We obtained de-identified demographic, staging, and treatment information on gastric adenocarcinoma (GA) pts 18-90 y/o diagnosed between 2004-2013 from the National Cancer Database. The cohort was divided into young adults (YAs, 18-39 y/o), extreme elderly pts (EE, 75-90 y/o) and remaining pts into a middle age group (MA, 40-74 y/o). Differences amongst the groups were evaluated and compared using Pearson's chi-squared test.


The total cohort included 118,417 pts: YAs (n = 3,997, 3.4%), MA (n = 77,292 65.3%), and EE (n= 37,128, 31.3%). Results are summarized as percentages in the table to reflect effect size given the large cohort. All differences amongst the groups were statistically significant (p  75 years old, a higher proportion of whom are not treated.

Sex (N = 118,417) Male/Female 52.8%/47.2% 66.6%/33.4% 58.1%/41.9%
Race (N = 115,372) White/Black/Asian 72.0%/ 18.5%/ 9.5% 76.6%/ 16.6%/ 6.8% 80.9%/ 12.9%/ 6.1%
Ethnicity (N = 111,467) Hispanic/non-Hispanic 29.6%/70.3% 11.3%/88.7% 7.2%/92.8%
Stage (N = 118,417) I/II/III/IV 16.0%/10.5%/18.4%/55.2% 22.9%/15.2%/21.1%/40.9% 30.5%/16.0%/18.4%/35.1%
Grade (N = 94,326) 1/2/3 6.2%/13.9%/79.9% 7.6%/26.9%/65.5% 7.5%/32.4%/60.1%
Subtype (N = 11,110) Intestinal/diffuse 30.3%/69.7% 66.7%/33.3% 80.1%/19.9%
Treatment (N = 82,765) Surgery Surgery + chemo Surgery + chemoRT None 25.7% 23.6% 28.8% 21.8% 34.6% 17.3% 27.6% 20.4% 47.9% 7.2% 8.7% 36.2%


Differences exist between age extremes in GA patients compared to those traditionally represented in landmark trials including demographics, stage of presentation, histologic subtype, and treatment utilization. Further investigation is warranted to determine the effects of these differences on outcome.

Clinical trial identification

Legal entity responsible for the study

This study is a retrospective review. No legal entities were involved in the conduct of this study.


Mount Sinai School of Medicine


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings